Biosimilar Monoclonal Antibodies Market
1 Study Coverage
1.1 Biosimilar Monoclonal Antibodies Product Introduction
1.2 Market by Type
1.2.1 Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Infliximab
1.2.3 Rituximab
1.2.4 Trastuzumab
1.2.5 Adalimumab
1.2.6 Other
1.3 Market by Application
1.3.1 Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Oncology
1.3.3 Autoimmune Disease
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Biosimilar Monoclonal Antibodies Sales Estimates and Forecasts 2017-2028
2.2 Global Biosimilar Monoclonal Antibodies Revenue Estimates and Forecasts 2017-2028
2.3 Global Biosimilar Monoclonal Antibodies Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Biosimilar Monoclonal Antibodies Sales by Region
2.4.1 Global Biosimilar Monoclonal Antibodies Sales by Region (2017-2022)
2.4.2 Global Sales Biosimilar Monoclonal Antibodies by Region (2023-2028)
2.5 Global Biosimilar Monoclonal Antibodies Revenue by Region
2.5.1 Global Biosimilar Monoclonal Antibodies Revenue by Region (2017-2022)
2.5.2 Global Biosimilar Monoclonal Antibodies Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Biosimilar Monoclonal Antibodies Sales by Manufacturers
3.1.1 Global Top Biosimilar Monoclonal Antibodies Manufacturers by Sales (2017-2022)
3.1.2 Global Biosimilar Monoclonal Antibodies Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Biosimilar Monoclonal Antibodies in 2021
3.2 Global Biosimilar Monoclonal Antibodies Revenue by Manufacturers
3.2.1 Global Biosimilar Monoclonal Antibodies Revenue by Manufacturers (2017-2022)
3.2.2 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Biosimilar Monoclonal Antibodies Revenue in 2021
3.3 Global Biosimilar Monoclonal Antibodies Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Biosimilar Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Biosimilar Monoclonal Antibodies Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Biosimilar Monoclonal Antibodies Sales by Type
4.1.1 Global Biosimilar Monoclonal Antibodies Historical Sales by Type (2017-2022)
4.1.2 Global Biosimilar Monoclonal Antibodies Forecasted Sales by Type (2023-2028)
4.1.3 Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2017-2028)
4.2 Global Biosimilar Monoclonal Antibodies Revenue by Type
4.2.1 Global Biosimilar Monoclonal Antibodies Historical Revenue by Type (2017-2022)
4.2.2 Global Biosimilar Monoclonal Antibodies Forecasted Revenue by Type (2023-2028)
4.2.3 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2017-2028)
4.3 Global Biosimilar Monoclonal Antibodies Price by Type
4.3.1 Global Biosimilar Monoclonal Antibodies Price by Type (2017-2022)
4.3.2 Global Biosimilar Monoclonal Antibodies Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Biosimilar Monoclonal Antibodies Sales by Application
5.1.1 Global Biosimilar Monoclonal Antibodies Historical Sales by Application (2017-2022)
5.1.2 Global Biosimilar Monoclonal Antibodies Forecasted Sales by Application (2023-2028)
5.1.3 Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2017-2028)
5.2 Global Biosimilar Monoclonal Antibodies Revenue by Application
5.2.1 Global Biosimilar Monoclonal Antibodies Historical Revenue by Application (2017-2022)
5.2.2 Global Biosimilar Monoclonal Antibodies Forecasted Revenue by Application (2023-2028)
5.2.3 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2017-2028)
5.3 Global Biosimilar Monoclonal Antibodies Price by Application
5.3.1 Global Biosimilar Monoclonal Antibodies Price by Application (2017-2022)
5.3.2 Global Biosimilar Monoclonal Antibodies Price Forecast by Application (2023-2028)
6 North America
6.1 North America Biosimilar Monoclonal Antibodies Market Size by Type
6.1.1 North America Biosimilar Monoclonal Antibodies Sales by Type (2017-2028)
6.1.2 North America Biosimilar Monoclonal Antibodies Revenue by Type (2017-2028)
6.2 North America Biosimilar Monoclonal Antibodies Market Size by Application
6.2.1 North America Biosimilar Monoclonal Antibodies Sales by Application (2017-2028)
6.2.2 North America Biosimilar Monoclonal Antibodies Revenue by Application (2017-2028)
6.3 North America Biosimilar Monoclonal Antibodies Market Size by Country
6.3.1 North America Biosimilar Monoclonal Antibodies Sales by Country (2017-2028)
6.3.2 North America Biosimilar Monoclonal Antibodies Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Biosimilar Monoclonal Antibodies Market Size by Type
7.1.1 Europe Biosimilar Monoclonal Antibodies Sales by Type (2017-2028)
7.1.2 Europe Biosimilar Monoclonal Antibodies Revenue by Type (2017-2028)
7.2 Europe Biosimilar Monoclonal Antibodies Market Size by Application
7.2.1 Europe Biosimilar Monoclonal Antibodies Sales by Application (2017-2028)
7.2.2 Europe Biosimilar Monoclonal Antibodies Revenue by Application (2017-2028)
7.3 Europe Biosimilar Monoclonal Antibodies Market Size by Country
7.3.1 Europe Biosimilar Monoclonal Antibodies Sales by Country (2017-2028)
7.3.2 Europe Biosimilar Monoclonal Antibodies Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Biosimilar Monoclonal Antibodies Market Size by Type
8.1.1 Asia Pacific Biosimilar Monoclonal Antibodies Sales by Type (2017-2028)
8.1.2 Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Type (2017-2028)
8.2 Asia Pacific Biosimilar Monoclonal Antibodies Market Size by Application
8.2.1 Asia Pacific Biosimilar Monoclonal Antibodies Sales by Application (2017-2028)
8.2.2 Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Application (2017-2028)
8.3 Asia Pacific Biosimilar Monoclonal Antibodies Market Size by Region
8.3.1 Asia Pacific Biosimilar Monoclonal Antibodies Sales by Region (2017-2028)
8.3.2 Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Biosimilar Monoclonal Antibodies Market Size by Type
9.1.1 Latin America Biosimilar Monoclonal Antibodies Sales by Type (2017-2028)
9.1.2 Latin America Biosimilar Monoclonal Antibodies Revenue by Type (2017-2028)
9.2 Latin America Biosimilar Monoclonal Antibodies Market Size by Application
9.2.1 Latin America Biosimilar Monoclonal Antibodies Sales by Application (2017-2028)
9.2.2 Latin America Biosimilar Monoclonal Antibodies Revenue by Application (2017-2028)
9.3 Latin America Biosimilar Monoclonal Antibodies Market Size by Country
9.3.1 Latin America Biosimilar Monoclonal Antibodies Sales by Country (2017-2028)
9.3.2 Latin America Biosimilar Monoclonal Antibodies Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Biosimilar Monoclonal Antibodies Market Size by Type
10.1.1 Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Type (2017-2028)
10.1.2 Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Type (2017-2028)
10.2 Middle East and Africa Biosimilar Monoclonal Antibodies Market Size by Application
10.2.1 Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Application (2017-2028)
10.2.2 Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Application (2017-2028)
10.3 Middle East and Africa Biosimilar Monoclonal Antibodies Market Size by Country
10.3.1 Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2017-2028)
10.3.2 Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Celltrion
11.1.1 Celltrion Corporation Information
11.1.2 Celltrion Overview
11.1.3 Celltrion Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Celltrion Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Celltrion Recent Developments
11.2 Pfizer (Hospira)
11.2.1 Pfizer (Hospira) Corporation Information
11.2.2 Pfizer (Hospira) Overview
11.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Pfizer (Hospira) Recent Developments
11.3 3SBIO
11.3.1 3SBIO Corporation Information
11.3.2 3SBIO Overview
11.3.3 3SBIO Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 3SBIO Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 3SBIO Recent Developments
11.4 Novartis (Sandoz)
11.4.1 Novartis (Sandoz) Corporation Information
11.4.2 Novartis (Sandoz) Overview
11.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Novartis (Sandoz) Recent Developments
11.5 Dr Reddy?s
11.5.1 Dr Reddy?s Corporation Information
11.5.2 Dr Reddy?s Overview
11.5.3 Dr Reddy?s Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Dr Reddy?s Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Dr Reddy?s Recent Developments
11.6 Celgen Biopharma
11.6.1 Celgen Biopharma Corporation Information
11.6.2 Celgen Biopharma Overview
11.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Celgen Biopharma Recent Developments
11.7 Cadila Healthcare
11.7.1 Cadila Healthcare Corporation Information
11.7.2 Cadila Healthcare Overview
11.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Cadila Healthcare Recent Developments
11.8 Hisun Pharma
11.8.1 Hisun Pharma Corporation Information
11.8.2 Hisun Pharma Overview
11.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Hisun Pharma Recent Developments
11.9 Torrent Pharmaceuticals
11.9.1 Torrent Pharmaceuticals Corporation Information
11.9.2 Torrent Pharmaceuticals Overview
11.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Torrent Pharmaceuticals Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Biosimilar Monoclonal Antibodies Industry Chain Analysis
12.2 Biosimilar Monoclonal Antibodies Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Biosimilar Monoclonal Antibodies Production Mode & Process
12.4 Biosimilar Monoclonal Antibodies Sales and Marketing
12.4.1 Biosimilar Monoclonal Antibodies Sales Channels
12.4.2 Biosimilar Monoclonal Antibodies Distributors
12.5 Biosimilar Monoclonal Antibodies Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Biosimilar Monoclonal Antibodies Industry Trends
13.2 Biosimilar Monoclonal Antibodies Market Drivers
13.3 Biosimilar Monoclonal Antibodies Market Challenges
13.4 Biosimilar Monoclonal Antibodies Market Restraints
14 Key Findings in The Global Biosimilar Monoclonal Antibodies Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Infliximab
Table 3. Major Manufacturers of Rituximab
Table 4. Major Manufacturers of Trastuzumab
Table 5. Major Manufacturers of Adalimumab
Table 6. Major Manufacturers of Other
Table 7. Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Biosimilar Monoclonal Antibodies Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 9. Global Biosimilar Monoclonal Antibodies Sales by Region (2017-2022) & (K Units)
Table 10. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2017-2022)
Table 11. Global Biosimilar Monoclonal Antibodies Sales by Region (2023-2028) & (K Units)
Table 12. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2023-2028)
Table 13. Global Biosimilar Monoclonal Antibodies Revenue by Region (2017-2022) & (US$ Million)
Table 14. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2017-2022)
Table 15. Global Biosimilar Monoclonal Antibodies Revenue by Region (2023-2028) & (US$ Million)
Table 16. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2023-2028)
Table 17. Global Biosimilar Monoclonal Antibodies Sales by Manufacturers (2017-2022) & (K Units)
Table 18. Global Biosimilar Monoclonal Antibodies Sales Share by Manufacturers (2017-2022)
Table 19. Global Biosimilar Monoclonal Antibodies Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 20. Global Biosimilar Monoclonal Antibodies Revenue Share by Manufacturers (2017-2022)
Table 21. Biosimilar Monoclonal Antibodies Price by Manufacturers (2017-2022) &(USD/Unit)
Table 22. Global Biosimilar Monoclonal Antibodies Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Biosimilar Monoclonal Antibodies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Monoclonal Antibodies as of 2021)
Table 24. Biosimilar Monoclonal Antibodies Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Biosimilar Monoclonal Antibodies Product Offered
Table 26. Date of Manufacturers Enter into Biosimilar Monoclonal Antibodies Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Biosimilar Monoclonal Antibodies Sales by Type (2017-2022) & (K Units)
Table 29. Global Biosimilar Monoclonal Antibodies Sales by Type (2023-2028) & (K Units)
Table 30. Global Biosimilar Monoclonal Antibodies Sales Share by Type (2017-2022)
Table 31. Global Biosimilar Monoclonal Antibodies Sales Share by Type (2023-2028)
Table 32. Global Biosimilar Monoclonal Antibodies Revenue by Type (2017-2022) & (US$ Million)
Table 33. Global Biosimilar Monoclonal Antibodies Revenue by Type (2023-2028) & (US$ Million)
Table 34. Global Biosimilar Monoclonal Antibodies Revenue Share by Type (2017-2022)
Table 35. Global Biosimilar Monoclonal Antibodies Revenue Share by Type (2023-2028)
Table 36. Biosimilar Monoclonal Antibodies Price by Type (2017-2022) & (USD/Unit)
Table 37. Global Biosimilar Monoclonal Antibodies Price Forecast by Type (2023-2028) & (USD/Unit)
Table 38. Global Biosimilar Monoclonal Antibodies Sales by Application (2017-2022) & (K Units)
Table 39. Global Biosimilar Monoclonal Antibodies Sales by Application (2023-2028) & (K Units)
Table 40. Global Biosimilar Monoclonal Antibodies Sales Share by Application (2017-2022)
Table 41. Global Biosimilar Monoclonal Antibodies Sales Share by Application (2023-2028)
Table 42. Global Biosimilar Monoclonal Antibodies Revenue by Application (2017-2022) & (US$ Million)
Table 43. Global Biosimilar Monoclonal Antibodies Revenue by Application (2023-2028) & (US$ Million)
Table 44. Global Biosimilar Monoclonal Antibodies Revenue Share by Application (2017-2022)
Table 45. Global Biosimilar Monoclonal Antibodies Revenue Share by Application (2023-2028)
Table 46. Biosimilar Monoclonal Antibodies Price by Application (2017-2022) & (USD/Unit)
Table 47. Global Biosimilar Monoclonal Antibodies Price Forecast by Application (2023-2028) & (USD/Unit)
Table 48. North America Biosimilar Monoclonal Antibodies Sales by Type (2017-2022) & (K Units)
Table 49. North America Biosimilar Monoclonal Antibodies Sales by Type (2023-2028) & (K Units)
Table 50. North America Biosimilar Monoclonal Antibodies Revenue by Type (2017-2022) & (US$ Million)
Table 51. North America Biosimilar Monoclonal Antibodies Revenue by Type (2023-2028) & (US$ Million)
Table 52. North America Biosimilar Monoclonal Antibodies Sales by Application (2017-2022) & (K Units)
Table 53. North America Biosimilar Monoclonal Antibodies Sales by Application (2023-2028) & (K Units)
Table 54. North America Biosimilar Monoclonal Antibodies Revenue by Application (2017-2022) & (US$ Million)
Table 55. North America Biosimilar Monoclonal Antibodies Revenue by Application (2023-2028) & (US$ Million)
Table 56. North America Biosimilar Monoclonal Antibodies Sales by Country (2017-2022) & (K Units)
Table 57. North America Biosimilar Monoclonal Antibodies Sales by Country (2023-2028) & (K Units)
Table 58. North America Biosimilar Monoclonal Antibodies Revenue by Country (2017-2022) & (US$ Million)
Table 59. North America Biosimilar Monoclonal Antibodies Revenue by Country (2023-2028) & (US$ Million)
Table 60. Europe Biosimilar Monoclonal Antibodies Sales by Type (2017-2022) & (K Units)
Table 61. Europe Biosimilar Monoclonal Antibodies Sales by Type (2023-2028) & (K Units)
Table 62. Europe Biosimilar Monoclonal Antibodies Revenue by Type (2017-2022) & (US$ Million)
Table 63. Europe Biosimilar Monoclonal Antibodies Revenue by Type (2023-2028) & (US$ Million)
Table 64. Europe Biosimilar Monoclonal Antibodies Sales by Application (2017-2022) & (K Units)
Table 65. Europe Biosimilar Monoclonal Antibodies Sales by Application (2023-2028) & (K Units)
Table 66. Europe Biosimilar Monoclonal Antibodies Revenue by Application (2017-2022) & (US$ Million)
Table 67. Europe Biosimilar Monoclonal Antibodies Revenue by Application (2023-2028) & (US$ Million)
Table 68. Europe Biosimilar Monoclonal Antibodies Sales by Country (2017-2022) & (K Units)
Table 69. Europe Biosimilar Monoclonal Antibodies Sales by Country (2023-2028) & (K Units)
Table 70. Europe Biosimilar Monoclonal Antibodies Revenue by Country (2017-2022) & (US$ Million)
Table 71. Europe Biosimilar Monoclonal Antibodies Revenue by Country (2023-2028) & (US$ Million)
Table 72. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Type (2017-2022) & (K Units)
Table 73. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Type (2023-2028) & (K Units)
Table 74. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Type (2017-2022) & (US$ Million)
Table 75. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Type (2023-2028) & (US$ Million)
Table 76. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Application (2017-2022) & (K Units)
Table 77. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Application (2023-2028) & (K Units)
Table 78. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Application (2017-2022) & (US$ Million)
Table 79. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Application (2023-2028) & (US$ Million)
Table 80. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Region (2017-2022) & (K Units)
Table 81. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Region (2023-2028) & (K Units)
Table 82. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Region (2017-2022) & (US$ Million)
Table 83. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Region (2023-2028) & (US$ Million)
Table 84. Latin America Biosimilar Monoclonal Antibodies Sales by Type (2017-2022) & (K Units)
Table 85. Latin America Biosimilar Monoclonal Antibodies Sales by Type (2023-2028) & (K Units)
Table 86. Latin America Biosimilar Monoclonal Antibodies Revenue by Type (2017-2022) & (US$ Million)
Table 87. Latin America Biosimilar Monoclonal Antibodies Revenue by Type (2023-2028) & (US$ Million)
Table 88. Latin America Biosimilar Monoclonal Antibodies Sales by Application (2017-2022) & (K Units)
Table 89. Latin America Biosimilar Monoclonal Antibodies Sales by Application (2023-2028) & (K Units)
Table 90. Latin America Biosimilar Monoclonal Antibodies Revenue by Application (2017-2022) & (US$ Million)
Table 91. Latin America Biosimilar Monoclonal Antibodies Revenue by Application (2023-2028) & (US$ Million)
Table 92. Latin America Biosimilar Monoclonal Antibodies Sales by Country (2017-2022) & (K Units)
Table 93. Latin America Biosimilar Monoclonal Antibodies Sales by Country (2023-2028) & (K Units)
Table 94. Latin America Biosimilar Monoclonal Antibodies Revenue by Country (2017-2022) & (US$ Million)
Table 95. Latin America Biosimilar Monoclonal Antibodies Revenue by Country (2023-2028) & (US$ Million)
Table 96. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Type (2017-2022) & (K Units)
Table 97. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Type (2023-2028) & (K Units)
Table 98. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Type (2017-2022) & (US$ Million)
Table 99. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Type (2023-2028) & (US$ Million)
Table 100. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Application (2017-2022) & (K Units)
Table 101. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Application (2023-2028) & (K Units)
Table 102. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Application (2017-2022) & (US$ Million)
Table 103. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Application (2023-2028) & (US$ Million)
Table 104. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2017-2022) & (K Units)
Table 105. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2023-2028) & (K Units)
Table 106. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country (2017-2022) & (US$ Million)
Table 107. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country (2023-2028) & (US$ Million)
Table 108. Celltrion Corporation Information
Table 109. Celltrion Description and Major Businesses
Table 110. Celltrion Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 111. Celltrion Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. Celltrion Recent Developments
Table 113. Pfizer (Hospira) Corporation Information
Table 114. Pfizer (Hospira) Description and Major Businesses
Table 115. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 116. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. Pfizer (Hospira) Recent Developments
Table 118. 3SBIO Corporation Information
Table 119. 3SBIO Description and Major Businesses
Table 120. 3SBIO Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 121. 3SBIO Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. 3SBIO Recent Developments
Table 123. Novartis (Sandoz) Corporation Information
Table 124. Novartis (Sandoz) Description and Major Businesses
Table 125. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 126. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. Novartis (Sandoz) Recent Developments
Table 128. Dr Reddy?s Corporation Information
Table 129. Dr Reddy?s Description and Major Businesses
Table 130. Dr Reddy?s Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 131. Dr Reddy?s Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. Dr Reddy?s Recent Developments
Table 133. Celgen Biopharma Corporation Information
Table 134. Celgen Biopharma Description and Major Businesses
Table 135. Celgen Biopharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 136. Celgen Biopharma Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. Celgen Biopharma Recent Developments
Table 138. Cadila Healthcare Corporation Information
Table 139. Cadila Healthcare Description and Major Businesses
Table 140. Cadila Healthcare Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 141. Cadila Healthcare Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
Table 142. Cadila Healthcare Recent Developments
Table 143. Hisun Pharma Corporation Information
Table 144. Hisun Pharma Description and Major Businesses
Table 145. Hisun Pharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 146. Hisun Pharma Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
Table 147. Hisun Pharma Recent Developments
Table 148. Torrent Pharmaceuticals Corporation Information
Table 149. Torrent Pharmaceuticals Description and Major Businesses
Table 150. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 151. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications
Table 152. Torrent Pharmaceuticals Recent Developments
Table 153. Key Raw Materials Lists
Table 154. Raw Materials Key Suppliers Lists
Table 155. Biosimilar Monoclonal Antibodies Distributors List
Table 156. Biosimilar Monoclonal Antibodies Customers List
Table 157. Biosimilar Monoclonal Antibodies Market Trends
Table 158. Biosimilar Monoclonal Antibodies Market Drivers
Table 159. Biosimilar Monoclonal Antibodies Market Challenges
Table 160. Biosimilar Monoclonal Antibodies Market Restraints
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources
List of Figures
Figure 1. Biosimilar Monoclonal Antibodies Product Picture
Figure 3. Global Biosimilar Monoclonal Antibodies Market Share by Type in 2021 & 2028
Figure 3. Infliximab Product Picture
Figure 4. Rituximab Product Picture
Figure 5. Trastuzumab Product Picture
Figure 6. Adalimumab Product Picture
Figure 7. Other Product Picture
Figure 8. Global Biosimilar Monoclonal Antibodies Market Share by Application in 2021 & 2028
Figure 9. Oncology
Figure 10. Autoimmune Disease
Figure 11. Other
Figure 12. Biosimilar Monoclonal Antibodies Report Years Considered
Figure 13. Global Biosimilar Monoclonal Antibodies Sales 2017-2028 (K Units)
Figure 14. Global Biosimilar Monoclonal Antibodies Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 15. Global Biosimilar Monoclonal Antibodies Revenue 2017-2028 (US$ Million)
Figure 16. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 17. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2017-2022)
Figure 18. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2023-2028)
Figure 19. North America Biosimilar Monoclonal Antibodies Sales YoY (2017-2028) & (K Units)
Figure 20. North America Biosimilar Monoclonal Antibodies Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Europe Biosimilar Monoclonal Antibodies Sales YoY (2017-2028) & (K Units)
Figure 22. Europe Biosimilar Monoclonal Antibodies Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Asia-Pacific Biosimilar Monoclonal Antibodies Sales YoY (2017-2028) & (K Units)
Figure 24. Asia-Pacific Biosimilar Monoclonal Antibodies Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Latin America Biosimilar Monoclonal Antibodies Sales YoY (2017-2028) & (K Units)
Figure 26. Latin America Biosimilar Monoclonal Antibodies Revenue YoY (2017-2028) & (US$ Million)
Figure 27. Middle East & Africa Biosimilar Monoclonal Antibodies Sales YoY (2017-2028) & (K Units)
Figure 28. Middle East & Africa Biosimilar Monoclonal Antibodies Revenue YoY (2017-2028) & (US$ Million)
Figure 29. The Biosimilar Monoclonal Antibodies Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 30. The Top 5 and 10 Largest Manufacturers of Biosimilar Monoclonal Antibodies in the World: Market Share by Biosimilar Monoclonal Antibodies Revenue in 2021
Figure 31. Global Biosimilar Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 32. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2017-2028)
Figure 33. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2017-2028)
Figure 34. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2017-2028)
Figure 35. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2017-2028)
Figure 36. North America Biosimilar Monoclonal Antibodies Sales Market Share by Type (2017-2028)
Figure 37. North America Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2017-2028)
Figure 38. North America Biosimilar Monoclonal Antibodies Sales Market Share by Application (2017-2028)
Figure 39. North America Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2017-2028)
Figure 40. North America Biosimilar Monoclonal Antibodies Sales Share by Country (2017-2028)
Figure 41. North America Biosimilar Monoclonal Antibodies Revenue Share by Country (2017-2028)
Figure 42. U.S. Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 43. Canada Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 44. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Type (2017-2028)
Figure 45. Europe Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2017-2028)
Figure 46. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Application (2017-2028)
Figure 47. Europe Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2017-2028)
Figure 48. Europe Biosimilar Monoclonal Antibodies Sales Share by Country (2017-2028)
Figure 49. Europe Biosimilar Monoclonal Antibodies Revenue Share by Country (2017-2028)
Figure 50. Germany Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 51. France Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 52. U.K. Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 53. Italy Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 54. Russia Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 55. Asia Pacific Biosimilar Monoclonal Antibodies Sales Market Share by Type (2017-2028)
Figure 56. Asia Pacific Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2017-2028)
Figure 57. Asia Pacific Biosimilar Monoclonal Antibodies Sales Market Share by Application (2017-2028)
Figure 58. Asia Pacific Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2017-2028)
Figure 59. Asia Pacific Biosimilar Monoclonal Antibodies Sales Share by Region (2017-2028)
Figure 60. Asia Pacific Biosimilar Monoclonal Antibodies Revenue Share by Region (2017-2028)
Figure 61. China Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 62. Japan Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 63. South Korea Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 64. India Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 65. Australia Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 66. Taiwan Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 67. Indonesia Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 68. Thailand Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 69. Malaysia Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 70. Philippines Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 71. Latin America Biosimilar Monoclonal Antibodies Sales Market Share by Type (2017-2028)
Figure 72. Latin America Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2017-2028)
Figure 73. Latin America Biosimilar Monoclonal Antibodies Sales Market Share by Application (2017-2028)
Figure 74. Latin America Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2017-2028)
Figure 75. Latin America Biosimilar Monoclonal Antibodies Sales Share by Country (2017-2028)
Figure 76. Latin America Biosimilar Monoclonal Antibodies Revenue Share by Country (2017-2028)
Figure 77. Mexico Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 78. Brazil Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 79. Argentina Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 80. Middle East and Africa Biosimilar Monoclonal Antibodies Sales Market Share by Type (2017-2028)
Figure 81. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2017-2028)
Figure 82. Middle East and Africa Biosimilar Monoclonal Antibodies Sales Market Share by Application (2017-2028)
Figure 83. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2017-2028)
Figure 84. Middle East and Africa Biosimilar Monoclonal Antibodies Sales Share by Country (2017-2028)
Figure 85. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue Share by Country (2017-2028)
Figure 86. Turkey Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 87. Saudi Arabia Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 88. U.A.E Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)
Figure 89. Biosimilar Monoclonal Antibodies Value Chain
Figure 90. Biosimilar Monoclonal Antibodies Production Process
Figure 91. Channels of Distribution
Figure 92. Distributors Profiles
Figure 93. Bottom-up and Top-down Approaches for This Report
Figure 94. Data Triangulation
Figure 95. Key Executives Interviewed
Industry Market Size
